Related Experiment Video
Updated: Jul 12, 2025
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
The Landscape of Randomized Clinical Trial Meta-analyses on Statins for Aneurysmal Subarachnoid Hemorrhage: A Scoping
Panagiotis Skouras1, Theodosis Kalamatianos1, Mariam Markouli2
11st Department of Neurosurgery, Evangelismos Hospital, National and Kapodistrian University of Athens, Greece.
Insights
Statins may offer benefits for patients with aneurysmal subarachnoid hemorrhage (aSAH), potentially reducing complications like cerebral vasospasm and improving outcomes. However, evidence is mixed, with some studies showing no significant effects.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Aneurysmal subarachnoid hemorrhage (aSAH) is a severe non-traumatic brain injury with high disability and mortality rates.
- Nimodipine is the sole established pharmacological treatment for improving outcomes in aSAH.
- The potential benefits of statin therapy in aSAH patients remain a subject of ongoing research and debate.
Purpose of the Study:
- To conduct a scoping review of meta-analyses of randomized clinical trials (RCTs) on statin use in aSAH.
- To analyze and map the existing literature regarding the efficacy of statins in managing aSAH.
Main Methods:
- Systematic search and analysis of meta-analyses of RCTs published between 2008 and 2023.
- Inclusion of 17 meta-analyses examining various statins (simvastatin, pravastatin, pitavastatin, atorvastatin).
Main Results:
- Eleven meta-analyses reported beneficial effects of statins, including reduced cerebral vasospasm, delayed cerebral ischemia, mortality, or improved neurological outcomes.
- Six meta-analyses found no significant beneficial effects of statin treatment in aSAH patients.
Conclusions:
- The efficacy of statins in aSAH is not definitively established, with conflicting results across meta-analyses.
- Limitations in existing research include small patient numbers, data quality issues, and heterogeneity in trial designs and outcome evaluations.
- Future research should address these limitations to clarify the role of statins in aSAH management.
Introduction:
Aneurysmal subarachnoid hemorrhage (aSAH) is a type of non-traumatic SAH that can have detrimental effects on the central nervous system, resulting in severe disability or death.
Methods:
Early nimodipine is currently the only strongly recommended pharmacological treatment that has shown efficacy in improving neurological/functional outcomes in aSAH patients. Whether statin treatment is of benefit to aSAH patients is an issue that has generated considerable interest and debate. In the present scoping review, we mapped and analyzed the available literature on metaanalyses of randomized clinical trials (RCTs) examining the effect of statins on aSAH. Seventeen meta-analyses of RCTs, published between 2008 and 2023, were identified.
Results:
Treatments in included meta-analyses were based on various regimens of simvastatin, pravastatin, pitavastatin or atorvastatin for up to 21 days. Eleven of the included reports indicated some beneficial effect of statin treatment, reducing rates of at least one of the following: cerebral vasospasm, delayed cerebral ischemia/delayed ischemic neurologic deficit, mortality or functional/ neurological outcome. In contrast, six meta-analyses, showed no such effects.
Conclusion:
The limitations reported by several meta-analyses, included low patient numbers or disproportionate representation of patients from certain RCTs, differences in drug treatment, patient diagnostic criteria and outcome evaluation between RCTs, as well as poor data quality or lack of RCTs data. Knowledge of the reported limitations may aid the design of future clinical trials and/or their meta-analyses.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:12Hazard Ratio
For example, in a clinical trial...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...